Articles

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Cancer Research and Biostatistics, Seattle, WA, USA
Cancer Research and Biostatistics, Seattle, WA, USA
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Cancer Research and Biostatistics, Seattle, WA, USA
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Cancer Research and Biostatistics, Seattle, WA, USA
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
Vol. 97 No. 11 (2012): November, 2012 https://doi.org/10.3324/haematol.2012.065698